QCG
KURA icon

Quadrant Capital Group’s Kura Oncology KURA Stock Holding History

Quadrant Capital Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.6K Buy
2,900
+1,066
+58% +$9.16K ﹤0.01% 1948
2025
Q4 		$19.1K Hold
1,834
– – ﹤0.01% 2014
2025
Q3 		$16.2K Buy
+1,834
New +$13.1K ﹤0.01% 2017
2025
Q2 		– Sell
-2,344
Closed -$15.5K – 2019
2025
Q1 		$15.5K Buy
2,344
+714
+44% +$5.56K ﹤0.01% 2111
2024
Q4 		$14.2K Sell
1,630
-60
-4% -$863 ﹤0.01% 2017
2024
Q3 		$33K Sell
1,690
-7
-0.4% -$142 ﹤0.01% 1672
2024
Q2 		$34.9K Sell
1,697
-62
-4% -$1.27K ﹤0.01% 1588
2024
Q1 		$37.5K Buy
1,759
+69
+4% +$1.34K ﹤0.01% 1548
2023
Q4 		$24.3K Buy
1,690
+1,642
+3,421% +$16.1K ﹤0.01% 1724
2023
Q3 		$438 Buy
48
+30
+167% +$305 ﹤0.01% 2587
2023
Q2 		$191 Sell
18
-1,369
-99% -$16.2K ﹤0.01% 2658
2023
Q1 		$17K Buy
+1,387
New +$17.3K ﹤0.01% 1781
2022
Q3 		– Sell
-52
Closed -$1K – 2724
2022
Q2 		$1K Sell
52
-9
-15% -$129 ﹤0.01% 2390
2022
Q1 		$1K Buy
+61
New +$881 ﹤0.01% 2330
2020
Q2 		– Sell
-16
Closed – – 2315
2020
Q1 		$0 Buy
+16
New +$183 ﹤0.01% 2186

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's KURA Position: Q1 2026 in Review

Quadrant Capital Group increased its Kura Oncology (KURA) stake by 58% in Q1 2026, buying an estimated $9.16K and bringing the position to 2,900 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1948.

Quadrant Capital Group first reported a position in KURA in Q1 2020 and has held it in 15 quarters since. The position peaked at $37.5K in Q1 2024. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Quadrant Capital Group held 2,900 shares of Kura Oncology worth $23.6K as of Q1 2026.
  • Quadrant Capital Group bought 1,066 Kura Oncology shares in Q1 2026, an estimated $9.16K.
  • Kura Oncology made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1948 holding.
  • Quadrant Capital Group first reported a position in Kura Oncology in Q1 2020 and has held it in 15 quarters since.
  • Quadrant Capital Group's Kura Oncology position peaked at $37.5K in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.